# Safranal

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/safranal
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 4 / 10
**Category:** Compound
**Also Known As:** 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxaldehyde, saffron aldehyde, crocetin aldehyde, saffron volatile compound, monoterpene aldehyde from saffron, kesar volatile oil component

## Overview

Safranal is a monoterpene aldehyde derived from the carotenoid picrocrocin during saffron (Crocus sativus) drying and is one of saffron's primary bioactive compounds responsible for its characteristic aroma. It exerts its primary pharmacological effects through modulation of GABA-A receptors and inhibition of [serotonin reuptake](/ingredients/condition/mood), producing anxiolytic and [neuroprotective](/ingredients/condition/cognitive) actions documented in preclinical research.

## Health Benefits

• May reduce anxiety through GABA and [serotonin](/ingredients/condition/mood) pathway modulation (preliminary animal evidence only)
• Potentially supports mood regulation via CNS effects (preclinical studies only)
• May influence [neurotransmitter activity](/ingredients/condition/cognitive) similar to anxiety medications (animal models only)
• Possible neuroprotective properties through monoterpene mechanisms (in vitro evidence only)
• Could contribute to saffron's traditional calming effects (no human clinical trials available)

## Mechanism of Action

Safranal acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride ion influx and reducing neuronal excitability in a mechanism comparable to benzodiazepines. It also inhibits the reuptake of dopamine, norepinephrine, and [serotonin](/ingredients/condition/mood) by blocking their respective transporters, thereby increasing monoamine availability in the synaptic cleft. Additionally, safranal demonstrates antioxidant activity by scavenging [reactive oxygen species](/ingredients/condition/antioxidant) and inhibiting lipid peroxidation, and it may suppress neuro[inflammation](/ingredients/condition/inflammation) partly through downregulation of NF-κB signaling pathways.

## Clinical Summary

The majority of evidence for safranal comes from rodent studies, where doses of approximately 0.1–0.5 mg/kg produced anxiolytic effects comparable to diazepam in elevated plus-maze and open-field tests. Human clinical trials have focused predominantly on standardized saffron extract (containing a mixture of safranal, crocin, and picrocrocin) rather than isolated safranal, making it difficult to attribute specific outcomes solely to safranal. A 2013 randomized controlled trial using 30 mg/day of saffron extract (n=40) over 6 weeks reported significant reductions in Hamilton Anxiety Rating Scale scores, though safranal's individual contribution remains unquantified. Overall, evidence for isolated safranal in humans is virtually nonexistent, and all therapeutic claims must be considered preliminary pending dedicated clinical trials.

## Nutritional Profile

Safranal is a monoterpene aldehyde and volatile organic compound (C10H14O, molecular weight 150.22 g/mol), not a traditional nutritional ingredient and thus contains no meaningful macronutrients, vitamins, minerals, fiber, or protein. It is the primary aromatic constituent of saffron (Crocus sativus), comprising approximately 60-70% of saffron's volatile fraction and typically present at concentrations of 0.02-0.1% in dried saffron stigmas. As a bioactive phytochemical, it is derived from the thermal or enzymatic degradation of picrocrocin (a glycoside precursor) during drying. Safranal is highly lipophilic, which contributes to its ability to cross the blood-brain barrier and interact with CNS receptors. It is not consumed in isolated supplemental doses under normal dietary conditions; rather, it is ingested incidentally as part of saffron spice, where typical culinary use yields only microgram-level exposure (estimated 0.5-5 mcg per culinary serving of saffron at 30 mg). Bioavailability data in humans is extremely limited; animal studies suggest rapid absorption due to its lipophilic nature and low molecular weight. No caloric value is attributed to safranal at physiologically relevant exposure levels. It contains no dietary fiber, essential fatty acids, or micronutrients.

## Dosage & Preparation

No clinically studied dosage ranges for isolated safranal are available from human trials. Saffron of good quality contains approximately 2.5% volatile compounds including safranal, but specific dosing for the isolated compound lacks clinical context. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Safranal in the amounts naturally present in culinary saffron is generally regarded as safe, but isolated high-dose supplementation carries risks including sedation, hypotension, and potential uterotonic effects that make it contraindicated during pregnancy. Because safranal potentiates GABA-A receptor activity, concurrent use with benzodiazepines, barbiturates, alcohol, or other CNS depressants may produce additive sedative effects and should be avoided. It may also interact with serotonergic medications such as SSRIs, SNRIs, or MAO inhibitors, theoretically increasing the risk of [serotonin](/ingredients/condition/mood) syndrome due to its reuptake-inhibiting properties. No established safe upper limit for isolated safranal supplementation exists in human populations, and individuals on prescription psychiatric or anticoagulant medications should consult a healthcare provider before use.

## Scientific Research

The research dossier reveals a significant gap in human clinical evidence for isolated safranal, with no RCTs or meta-analyses documented. Available literature focuses primarily on preclinical animal and in vitro studies, with Rezaee et al. (2013) reviewing pharmacological activities emphasizing foundational preclinical CNS effects (PMC3637901).

## Historical & Cultural Context

While safranal itself lacks direct historical use documentation as it forms post-harvest, saffron (Crocus sativus) has been cultivated near Greece for millennia and used as a spice, seasoning, and coloring agent. Traditional systems emphasized whole saffron containing over 150 compounds rather than isolated safranal.

## Synergistic Combinations

Crocin, picrocrocin, whole saffron extract, GABA-supporting herbs, [serotonin](/ingredients/condition/mood) precursors

## Frequently Asked Questions

### What is safranal and where does it come from?

Safranal is a monoterpene aldehyde (chemical formula C10H14O) that forms from the hydrolysis and deglycosylation of picrocrocin during the drying of saffron stigmas from Crocus sativus. It accounts for roughly 60–70% of the volatile fraction of saffron and is primarily responsible for the spice's distinctive aroma. Unlike crocin and crocetin, safranal is not a carotenoid but rather a cyclohexene-based aldehyde produced through thermal degradation during processing.

### Does safranal work like an antidepressant?

Preclinical studies suggest safranal inhibits the reuptake of serotonin, dopamine, and norepinephrine by binding to their respective membrane transporters, a mechanism shared by SNRI-class antidepressants. In forced swim and tail suspension tests in rodents, safranal at doses of 0.05–0.5 mg/kg demonstrated antidepressant-like behavior, reducing immobility time comparably to fluoxetine. However, no controlled human trials have isolated safranal's antidepressant effect, so drawing direct comparisons to pharmaceutical antidepressants in clinical practice is premature.

### What is the recommended dosage of safranal?

No clinically validated dosage for isolated safranal supplementation in humans has been established. Most human research has used standardized saffron extracts dosed at 30 mg/day, which typically contain a defined ratio of crocin, picrocrocin, and safranal rather than pure safranal alone. Animal studies have used safranal at 0.1–0.5 mg/kg body weight, but these figures cannot be reliably extrapolated to human dosing without dedicated pharmacokinetic trials.

### Can safranal cause anxiety or sedation as a side effect?

At higher doses, safranal's potentiation of GABA-A receptors can produce pronounced sedation, and animal studies at doses above 1 mg/kg have shown motor coordination impairment and excessive CNS depression. At moderate doses in rodent models, the compound displays an anxiolytic rather than anxiogenic profile, but individual sensitivity in humans is unknown. Paradoxical anxiety or agitation, sometimes observed with GABAergic agents, has not been formally documented for safranal but cannot be excluded without adequate human safety trials.

### Is safranal safe to take with SSRIs or other psychiatric medications?

Combining safranal with SSRIs such as fluoxetine or sertraline carries a theoretical risk of serotonin syndrome because both agents increase synaptic serotonin availability through reuptake inhibition, though no confirmed cases involving safranal specifically have been published. Co-administration with benzodiazepines or other GABAergic drugs is also cautioned due to potential additive CNS depression. Patients taking prescription psychiatric medications should obtain medical guidance before using any saffron-derived supplement containing meaningful safranal concentrations.

### How does safranal compare to whole saffron extract for mood and anxiety support?

Safranal is a single isolated monoterpene compound from saffron, whereas whole saffron extract contains multiple bioactive compounds including crocin and safranal working synergistically. Limited evidence suggests safranal alone may have anxiolytic effects in animal models, but human studies predominantly use whole saffron extracts rather than safranal in isolation. The relative efficacy and bioavailability of purified safranal versus the complete saffron profile remain understudied in clinical populations.

### Is safranal safe during pregnancy and breastfeeding?

There is insufficient human safety data on safranal supplementation during pregnancy and breastfeeding, so use is not recommended without medical guidance. While saffron spice is traditionally used in cuisine at low levels, concentrated safranal supplementation has not been adequately studied in pregnant or nursing populations. Consult a healthcare provider before using safranal-containing supplements if you are pregnant, planning pregnancy, or breastfeeding.

### What does the current clinical research evidence show about safranal's effectiveness in humans?

Most evidence for safranal's anxiolytic and neuroprotective effects comes from preclinical animal studies and in vitro research, with very limited human clinical trials. The majority of human mood and anxiety research on saffron uses whole extract rather than isolated safranal, making it difficult to attribute effects specifically to safranal alone. Higher-quality, safranal-specific human studies are needed before strong clinical claims can be made about its efficacy.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*